MedTrace Logo

Clinical Trials

Showing trials with last updates posted in 2026.

NCT06737432 | ACTIVE_NOT_RECRUITING | NA
875 participants

Respiratory Knowledge Portal Computer and Phone Application to Improve Quality of Mechanical Ventilation by Reducing the Number of Ventilator Associated Events, Injury Created by the Ventilator and Unsafe Setting of Alarms.

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-03
Start Date:
2024-06-01
Completion:
2026-10-31
Conditions
  • Ventilation
  • ARDS
  • Respiratory Failure
  • Mechanical Ventilation
  • Ventilator-induced Lung Injury (VILI)
  • Quality Improvement
  • Ventilator Associated Events
Interventions
  • OTHER
No Results Yet
NCT06735573 | COMPLETED
13 participants

Protein, Sarcopenic Obesity, and COPD

Study Type:
OBSERVATIONAL
Last Updated:
2026-09-03
Start Date:
2026-01-01
Completion:
2026-08-27
Conditions
  • Sarcopenic Obesity
  • Chronic Obstructive Pulmonary Diseases
Interventions
  • OTHER
No Results Yet
NCT06725277 | RECRUITING
450 participants

The OBSERVE Protocol

Study Type:
OBSERVATIONAL
Last Updated:
2026-09-03
Start Date:
2024-01-21
Completion:
2029-12-31
Conditions
  • Major Depression Disorder
Interventions
  • DRUG
No Results Yet
NCT06717347 | RECRUITING | PHASE3
1046 participants

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-03
Start Date:
2025-01-27
Completion:
2029-07-02
Conditions
  • Diffuse Large B-Cell Lymphoma
Interventions
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT06649812 | RECRUITING | PHASE2
120 participants

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-03
Start Date:
2025-10-07
Completion:
2028-09-01
Conditions
  • High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
  • Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
  • Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT06635980 | RECRUITING | PHASE2
120 participants

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-03
Start Date:
2025-05-14
Completion:
2031-10-21
Conditions
  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Breast Carcinoma
  • Triple-Negative Breast Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • RADIATION
  • OTHER
No Results Yet
NCT06617169 | ACTIVE_NOT_RECRUITING | PHASE1
12 participants

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-03
Start Date:
2024-10-08
Completion:
2027-01-31
Conditions
  • Solid Tumor, Adult
  • Bladder Cancer
  • Urothelial Carcinoma
  • Triple-negative Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
Interventions
  • DRUG
No Results Yet
NCT06589804 | RECRUITING | PHASE3
158 participants

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-03
Start Date:
2025-03-27
Completion:
2029-11-30
Conditions
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Hypopharyngeal Squamous Cell Carcinoma
  • Metastatic Laryngeal Squamous Cell Carcinoma
  • Metastatic Oral Cavity Squamous Cell Carcinoma
  • Metastatic Oropharyngeal Squamous Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Squamous Cell Carcinoma
  • Recurrent Neck Squamous Cell Carcinoma of Unknown Primary
  • Recurrent Oral Cavity Squamous Cell Carcinoma
  • Recurrent Oropharyngeal Squamous Cell Carcinoma
  • Refractory Head and Neck Squamous Cell Carcinoma
  • Refractory Hypopharyngeal Squamous Cell Carcinoma
  • Refractory Laryngeal Squamous Cell Carcinoma
  • Refractory Oral Cavity Squamous Cell Carcinoma
  • Refractory Oropharyngeal Squamous Cell Carcinoma
  • Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage IV Hypopharyngeal Carcinoma AJCC v8
  • Stage IV Laryngeal Cancer AJCC v8
  • Stage IV Lip and Oral Cavity Cancer AJCC v8
  • Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
  • PROCEDURE
  • BIOLOGICAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page